CAS 820957-38-8: (3R,6R)-3-(2,3-Dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione

Retosiban is a pharmaceutical compound that serves as an oxytocin receptor antagonist, derived through synthetic chemical synthesis. Its primary mechanism of action involves the selective inhibition of oxytocin receptors, which are critical in the uterine contractions that occur during labor. By blocking these receptors, Retosiban effectively reduces uterine muscle contractions, thus playing a crucial role in managing preterm labor. The primary application of Retosiban is in the obstetric field, where it is used to delay preterm birth by reducing the frequency, intensity, and duration of uterine contractions. This can help to prolong pregnancy, allowing for further fetal development and reducing risks associated with premature delivery. Although still under investigation in various clinical trial stages, Retosiban holds promise as a significant intervention for improving neonatal outcomes in pregnancies at risk of preterm birth. Research continues to assess its efficacy, safety profile, and potential long-term impacts on both maternal and fetal health.

Retosiban is an effective and selective oxytocin antagonist (Ki: 0.65 nM).